Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Resmetirom Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Resmetirom Prior Authorization and Quantity Limits

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Rezdiffra (resmetirom) tablets for Boeing commercial members, including initial authorization, renewal, and quantity-limit exceptions. Coverage requires clinical criteria for noncirrhotic NASH/MASH with moderate-to-advanced fibrosis or another FDA-labeled indication, along with applicable safety, specialist, and documentation requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyResmetirom Prior Authorization and Quantity Limits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting the diagnosis, fibrosis stage or testing, alcohol consumption, relevant liver conditions, specialist involvement, and clinical benefit when required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered resmetirom strengths
    30/30 daysQuantity limit
    12 monthsApproval duration
    F2-F3NASH/MASH fibrosis stage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Covered when ALL applicable requirements are met, including ONE qualifying indication pathway:

    ONE qualifying pathway

    • Noncirrhotic NASH/MASH pathway

      • The patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis consistent with stages F2 to F3 fibrosis; medical records required.
      • Stage F2 or F3 fibrosis is confirmed, prior to therapy with the requested agent, by ONE of the following: liver biopsy within the past 2 years, vibration-controlled transient elastography (VCTE), enhanced liver fibrosis (ELF) score of 9.2 to 11.2, magnetic resonance elastography (MRE), or ultrasound-based elastography; medical records required.
      • ONE Wegovy-related criterion

        • The patient has tried and had an inadequate response after 72 weeks of therapy with Wegovy injection; chart notes required.
        • The patient has tried and had an inadequate response after 72 weeks of therapy with another subcutaneous GLP-1 agent for treatment of the requested indication; chart notes required.
        • The patient has an intolerance or hypersensitivity to therapy with Wegovy injection; chart notes required.
        • The patient has an FDA-labeled contraindication to Wegovy injection; chart notes required.
      • Alcohol consumption criterion

        • If the patient's sex is female, alcohol consumption is less than 20 grams per day; medical records required.
        • If the patient's sex is male, alcohol consumption is less than 30 grams per day; medical records required.
      • The patient is being monitored and/or treated for comorbid conditions, such as cardiovascular disease, diabetes, dyslipidemia, or hypertension.
      • ONE body-weight-management criterion

        • The patient's BMI is less than or equal to 23 kg/m^2 if the patient is of South Asian, Southeast Asian, or East Asian descent.
        • The patient's BMI is less than or equal to 25 kg/m^2.
        • ALL of the following

          • The patient is currently on a weight-management regimen consisting of a low-calorie diet, increased physical activity, and behavioral modifications.
          • The patient will continue the weight-management regimen in combination with the requested agent.
    • Other FDA-labeled indication pathway

      • The patient has another FDA-labeled indication for the requested agent.
      • ONE age criterion

        • The patient's age is within FDA labeling for the requested indication.
        • There is support for use of the requested agent for the patient's age for the requested indication.

    Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's prior authorization process. Patients not previously approved require initial evaluation review.
    • ONE indication pathway

      • NASH/MASH renewal pathway

        • The patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH); medical records required.
        • ONE alcohol consumption criterion

          • If the patient's sex is female, alcohol consumption is less than 20 grams per day; medical records required.

    Quantity-Limit Criteria

    The quantity limit for the target agent will be approved when ONE of the following is met:

    ONE quantity-limit basis

    • The requested quantity (dose) does not exceed the program quantity limit.
    • Quantity exceeds program limit

      • ONE exception basis

        • ALL of the following

          • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
          • There is support for therapy with a higher dose for the requested indication.
        • ALL of the following

    Coverage is excluded for patients with decompensated cirrhosis, moderate to severe hepatic impairment (Child-Pugh Class B or C), or any other liver disease, including Wilson's disease, hepatocellular carcinoma, or hepatitis.

    For renewal under the NASH/MASH pathway, coverage requires that the patient has not progressed to liver fibrosis stage F4.

    The patient must not have any FDA-labeled contraindications to the requested agent.

    Clinical Thresholds and Coding Details

    Enhanced liver fibrosis score
    Qualifying testEnhanced liver fibrosis (ELF) score
    Qualifying range9.2 to 11.2
    TimingThe score must confirm stage F2 or F3 fibrosis before resmetirom therapy
    Alcohol consumption
    Female thresholdAlcohol consumption less than 20 grams/day
    Male thresholdAlcohol consumption less than 30 grams/day
    DocumentationMedical records are required

    Provider Authorization Actions

    Prior Authorization

    Initial Authorization

    Submit a prior authorization request for resmetirom (Rezdiffra) and document one qualifying pathway for initial coverage. The primary pathway requires noncirrhotic NASH/MASH with moderate-to-advanced F2–F3 fibrosis; an alternative requires another FDA-labeled indication with age support. The patient must also meet the applicable exclusions, specialist involvement, and contraindication requirements.

    • Document noncirrhotic NASH/MASH with moderate-to-advanced liver fibrosis consistent with stages F2–F3.
    • Confirm F2–F3 fibrosis before therapy using one of: liver biopsy within 2 years, VCTE, ELF score 9.2–11.2, MRE, or ultrasound-based elastography.
    • Document alcohol consumption below 20 grams/day for female patients or below 30 grams/day for male patients.
    • Document monitoring or treatment of comorbidities, such as cardiovascular disease, diabetes, dyslipidemia, or hypertension.
    • Document either BMI ≤23 kg/m² for patients of South Asian, Southeast Asian, or East Asian descent, BMI ≤25 kg/m², or a continuing low-calorie diet, increased physical activity, and behavioral-modification regimen.
    • Confirm no decompensated cirrhosis, moderate-to-severe hepatic impairment (Child-Pugh B or C), or other liver disease such as Wilson disease, hepatocellular carcinoma, or hepatitis.
    • Identify a specialist prescriber or document specialist consultation, and confirm no FDA-labeled contraindication to the requested agent.

    Policy Background

    This policy addresses coverage of Rezdiffra (resmetirom) for noncirrhotic nonalcoholic steatohepatitis (NASH), also called metabolic dysfunction-associated steatohepatitis (MASH), when moderate-to-advanced liver fibrosis is present. The qualifying NASH/MASH fibrosis range for initial treatment is F2-F3, with fibrosis confirmed by an accepted liver assessment method before therapy. The policy also provides criteria for resmetirom used for another FDA-labeled indication, as well as requirements for initial authorization, renewal, and quantity-limit exceptions.

    Clinical Definitions

    NASH/MASH with F2-F3 fibrosis
    DiseaseNoncirrhotic nonalcoholic steatohepatitis (NASH), also termed metabolic dysfunction-associated steatohepatitis (MASH)
    Fibrosis severityModerate-to-advanced liver fibrosis consistent with stages F2 to F3
    Cirrhosis statusThe qualifying disease state is noncirrhotic
    Fibrosis confirmation
    Liver biopsyBiopsy performed within the past 2 years
    Transient elastographyVibration-controlled transient elastography (VCTE)
    ELF testing

    Initial Therapy Criteria

    Continuation and Renewal Criteria

    Resmetirom Renewal

    Renewal of Rezdiffra (resmetirom) requires prior plan approval, ONE qualifying continuation pathway, and all shared safety and specialist requirements.

    Shared renewal requirements

    • The patient was previously approved for resmetirom through the plan's prior authorization process.

      Patients without prior plan approval require initial evaluation.

    • Qualifying continuation pathway

      • NASH/MASH continuation

        • The patient has noncirrhotic NASH or MASH.
        • Alcohol consumption

    Step Therapy Requirement

    StepRequired therapyApplicable exception
    1Try Wegovy injection or another subcutaneous GLP-1 agent for the requested indication and demonstrate an inadequate response after 72 weeks of therapy.The requirement is met if the patient has intolerance or hypersensitivity to Wegovy injection, or an FDA-labeled contraindication to Wegovy injection.

    Quantity Limits by Strength

    Rezdiffra 60 mg tablets
    StrengthRezdiffra (resmetirom) 60 mg tablets
    Quantity limit30 tablets
    Supply periodPer 30 days
    Rezdiffra 80 mg tablets
    StrengthRezdiffra (resmetirom) 80 mg tablets
    Quantity limit30 tablets
    Supply periodPer 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyResmetirom Prior Authorization and Quantity Limits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting the diagnosis, fibrosis stage or testing, alcohol consumption, relevant liver conditions, specialist involvement, and clinical benefit when required.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsProvider Authorization ActionsPolicy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation and Renewal CriteriaStep Therapy RequirementQuantity Limits by Strength
    If the patient's sex is male, alcohol consumption is less than 30 grams per day; medical records required.
  1. ONE body-weight-management criterion

    • The patient's BMI is less than or equal to 23 kg/m^2 if the patient is of South Asian, Southeast Asian, or East Asian descent.
    • The patient's BMI is less than or equal to 25 kg/m^2.
    • ALL of the following

      • The patient is currently on a weight-management regimen consisting of a low-calorie diet, increased physical activity, and behavioral modifications.
      • The patient will continue the weight-management regimen in combination with the requested agent.
  2. The patient has NOT progressed to liver fibrosis stage F4; medical records required.
  3. Other indication renewal pathway

    • The patient has a diagnosis other than noncirrhotic NASH or MASH.
  4. The patient has had clinical benefit with the requested agent.
  5. The patient does NOT have decompensated cirrhosis, moderate to severe hepatic impairment (Child-Pugh Class B or C), or any other liver disease, such as Wilson's disease, hepatocellular carcinoma, or hepatitis; medical records required.
  6. The prescriber is a specialist in the area of the patient's diagnosis, such as a hepatologist or gastroenterologist, or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  7. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  8. The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
  9. There is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  10. BMI thresholds
    South Asian, Southeast Asian, or East Asian descentBMI less than or equal to 23 kg/m^2
    Standard criterionBMI less than or equal to 25 kg/m^2
    AlternativeThe patient may instead be on a continuing weight-management regimen of a low-calorie diet, increased physical activity, and behavioral modifications
    Prior GLP-1 therapy
    Required duration72 weeks
    Qualifying therapyWegovy injection or another subcutaneous GLP-1 agent for the requested indication
    Response requirementThe patient must have tried therapy and had an inadequate response
    Fibrosis stage
    Initial coverageNASH/MASH with moderate-to-advanced liver fibrosis consistent with stages F2 to F3
    Renewal requirementThe patient must not have progressed to liver fibrosis stage F4
    Renewal documentationMedical records are required to document fibrosis status
  11. For another FDA-labeled indication, document that the patient's age is within labeling or that there is support for use at the patient's age.
  12. Prior Authorization

    Renewal Authorization

    For renewal, document that the patient was previously approved through the plan's prior authorization process and continues to satisfy the applicable clinical pathway. Renewal approval is generally for 12 months.

    • Confirm prior plan approval; patients without prior approval require initial evaluation.
    • For NASH/MASH, document the diagnosis, alcohol threshold, applicable BMI or ongoing weight-management criteria, and that the patient has not progressed to F4 fibrosis.
    • For an indication other than NASH/MASH, document the diagnosis and clinical benefit from the requested agent.
    • For either pathway, confirm no decompensated cirrhosis, moderate-to-severe hepatic impairment (Child-Pugh B or C), other liver disease, or FDA-labeled contraindication.
    • Confirm specialist prescribing or specialist consultation.
    Prior Authorization

    Quantity-Limit Authorization

    If the requested dose exceeds the program quantity limit, submit a quantity-limit exception request with the requested dose, the applicable FDA-labeled maximum dose, and clinical support for the exception. Quantity-limit approvals are generally for 12 months.

    • The requested quantity is approvable when it does not exceed the program limit.
    • For a quantity above the limit, document either that no maximum FDA-labeled dose exists for the indication and that the higher dose is supported, or that the requested quantity does not exceed the maximum FDA-labeled dose and cannot be achieved with a lower quantity of a higher strength within the program limit.
    Step Therapy

    Prior GLP-1 Therapy Requirement

    Document the required prior GLP-1 therapy pathway for the NASH/MASH initial request. The record must show inadequate response after the required trial or establish an accepted exception.

    • Inadequate response after 72 weeks of Wegovy injection.
    • Inadequate response after 72 weeks of another subcutaneous GLP-1 agent used for the requested indication.
    • Intolerance or hypersensitivity to Wegovy injection.
    • An FDA-labeled contraindication to Wegovy injection.

    Unsupported block type: documentation

    Documentation Required

    Quantity-Limit Exception Documentation

    For a quantity-limit exception, provide enough information for the reviewer to compare the requested dose with the program limit and FDA-labeled maximum. Explain why the requested dose is clinically necessary and why an alternative lower quantity of a higher strength cannot be used when that option is relevant.

    • Requested dose and quantity, including strength and days' supply.
    • Applicable program quantity limit: 30 tablets per 30 days for Rezdiffra 60 mg, 80 mg, and 100 mg strengths.
    • Maximum FDA-labeled dose for the requested indication, if one exists.
    • Clinical support for a higher dose when no FDA-labeled maximum exists.
    • Clinical explanation that the requested quantity does not exceed the FDA-labeled maximum and cannot be achieved with a lower quantity of a higher strength within the program limit.
    Denial Risk

    Clinical Criteria Not Met

    Coverage may be denied when the request does not establish a covered indication or fails any required clinical condition. Surface and resolve these issues before submission or renewal.

    • No documented noncirrhotic NASH/MASH with F2–F3 fibrosis, or no supported alternative FDA-labeled indication and age criterion.
    • Fibrosis is not confirmed by an accepted test, or the patient has progressed to F4 fibrosis at renewal.
    • Alcohol use is at or above the applicable threshold: 20 grams/day or more for female patients, or 30 grams/day or more for male patients.
    • BMI exceeds the applicable threshold without the required ongoing weight-management regimen.
    • The patient is not monitored or treated for relevant comorbidities when required.
    • The required 72-week Wegovy or other subcutaneous GLP-1 inadequate-response trial is absent, or no accepted Wegovy intolerance, hypersensitivity, or contraindication is documented.
    • Decompensated cirrhosis, Child-Pugh B or C hepatic impairment, another liver disease, or an FDA-labeled contraindication is present.
    • Specialist prescribing or consultation, prior approval for renewal, or clinical benefit for a non-NASH/MASH renewal indication is not documented.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A quantity-limit exception is at risk of denial when the requested higher quantity is not tied to an applicable FDA-labeled dose or when the record does not explain why the program limit cannot be used.

    • The requested quantity exceeds 30 tablets per 30 days without a qualifying exception.
    • A maximum FDA-labeled dose exists and the requested quantity exceeds it.
    • No clinical support is provided for a higher dose when no FDA-labeled maximum exists.
    • The requested quantity could be achieved with a lower quantity of a higher strength that remains within the program limit, but the record does not explain why that alternative is not appropriate.
    • The request lacks the dose, strength, days' supply, program-limit comparison, or supporting clinical rationale.
    Enhanced liver fibrosis (ELF) score of 9.2 to 11.2
    Magnetic resonance testingMagnetic resonance elastography (MRE)
    Ultrasound testingUltrasound-based elastography
    Timing requirementConfirmation must occur before therapy with the requested agent
    The patient's sex is female and alcohol consumption is less than 20 grams/day.Less than 20 grams/day
  13. The patient's sex is male and alcohol consumption is less than 30 grams/day.Less than 30 grams/day
  14. BMI or continuing weight-management requirement

    • The patient is of South Asian, Southeast Asian, or East Asian descent and has a BMI less than or equal to 23 kg/m2.BMI <=23 kg/m2
    • The patient has a BMI less than or equal to 25 kg/m2.BMI <=25 kg/m2
    • ALL of the following

      • The patient is currently following a weight-management regimen of a low-calorie diet, increased physical activity, and behavioral modifications.
      • The patient will continue the weight-management regimen in combination with resmetirom.
  15. The patient has not progressed to liver fibrosis stage F4.No progression to F4 fibrosis
  16. Other diagnosis continuation

    • The patient has a diagnosis other than noncirrhotic NASH or MASH.
    • The patient has had clinical benefit with resmetirom.
  17. The patient does not have decompensated cirrhosis, moderate-to-severe hepatic impairment classified as Child-Pugh Class B or C, or another liver disease such as Wilson's disease, hepatocellular carcinoma, or hepatitis.
  18. The prescriber is a specialist in the area of the patient's diagnosis, such as a hepatologist or gastroenterologist, or has consulted with such a specialist.
  19. The patient does not have any FDA-labeled contraindication to resmetirom.
  20. Rezdiffra 100 mg tablets
    StrengthRezdiffra (resmetirom) 100 mg tablets
    Quantity limit30 tablets
    Supply periodPer 30 days